BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer

  April 7, 2026

   · 

  3 min read
• Press Releases

  Oculis to Participate in Upcoming Investor Conferences

  April 7, 2026

   · 

  4 min read
• Press Releases

  AlzeCure Pharma to Present at Redeye Healthcare Day on April 14

  April 7, 2026

   · 

  2 min read
• 

  Government

  FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic

  If the Trump administration’s proposal passes, the FDA’s budget will be more than $200 million bigger in 2027, with plans to launch new programs that expedite drug development, boost national security and promote “radical transparency.”

  April 7, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

  Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.

  April 7, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

  April 7, 2026

   · 

  8 min read
• Press Releases

  Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

  April 7, 2026

   · 

  5 min read
• Press Releases

  20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

  April 7, 2026

   · 

  5 min read
• Press Releases

  Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism

  April 7, 2026

   · 

  10 min read
• Press Releases

  Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

  April 7, 2026

   · 

  3 min read